|Place of Origin:||China|
|Model Number:||Lyophilized, 0.25g|
|Minimum Order Quantity:||100, 000 vials|
|Payment Terms:||L/C, T/T|
|Supply Ability:||300, 000 vials per day|
|Product:||Ganciclovir For Injection||Specification:||Lyophilized, 0.25g|
|Standard:||BP, USP||Packing:||50 Vials Per Box|
Ganciclovir for Injection 0.25g / Lyophilized Injection Ganciclovir
Product : Ganciclovir for Injection
Specification : Lyophilized, 0.25g
Standard : BP, USP
Packing : 50vials/box
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Ganciclovir is a synthetic nucleoside analogue of 2'-deoxyguanosine that inhibits replication of herpes viruses both in vitro and in vivo. Sensitive human viruses include cytomegalovirus (CMV), herpes simplex virus -1 and -2 (HSV-1, HSV-2), Epstein-Barr virus (EBV) and varicella zoster virus (VZV), however clinical studies have been limited to assessment of efficacy in patients with CMV infection. Ganciclovir is a prodrug that is structurally similar to acyclovir. It inhibits virus replication by its encorporation into viral DNA. This encorporation inhibits dATP and leads to defective DNA, ceasing or retarding the viral machinery required to spread the virus to other cells.
Mechanism of action :
Ganciclovir's antiviral activity inhibits virus replication. This inhibitory action is highly selective as the drug must be converted to the active form by a virus-encoded cellular enzyme, thymidine kinase (TK). TK catalyzes phosphorylation of ganciclovir to the monophosphate, which is then subsequently converted into the diphosphate by cellular guanylate kinase and into the triphosphate by a number of cellular enzymes. In vitro, ganciclovir triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, ganciclovir triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed.
Usual Adult Dosages :
1. To treat acute herpes keratitis (dendritic ulcers)
1 gtt 5 times daily (about every 3 hr while awake) until corneal ulcer heals; then 1 gtt three times a day for 7 days
2. To treat CMV infection
5 mg/kg I.V. over 1 hr every 12 hr for 14 to 21 days. Maintenance: 1,000 mg P.O. three times a day